142-Sm - a suitable positron emitter for uptake monitoring in 153-Sm EDTMP therapy
- CERN, Geneva (Switzerland); and others
The positron emitting isotopes {sup 86}Y and 83Sr are favoured candidates for monitoring the individual nuclide uptake in bone metastases with PET when {sup 90}Y or {sup 89}Sr are used in the therapy. It therefore seemed to be logical to propose the short-lived positron emitter {sup 142}Sm to perform the in vivo dosimetry in case cf {sup 153}Sm EDTMP therapy. {sup 142}Sm (72 min, 50 % positron branching) forms the 40 sec {sup 142}Pm with 95% positron decay rate. Three aspects will be discussed in the paper: the production of several GBq of the {sup 142}Sm in the required high quality, systematic studies of the biokinetic behaviour of radio-lanthanides with EDTMP as ligand and first dynamic PET studies using rabbits as animal model. Spallation reaction of 1 GeV protons interacting with a 100/g/cm{sup 2} Ta target in combination with an on line isotope separation process was used for the production of the radionuclides. The on line isotope separator facility ISOLDE at CERN provides excellent possibilities to produce {sup 142}Sm in multi GBq quantities, isotopically clean and carrier free. All other radio-lanthanides used in the study were produced at the ISOLDE facility as well. Using a number of long-lived radio-lanthanides we studied systematically the biokinetics of the lanthanides at different EDTMP concentrations and established clear relationships between biokinetics, EDTMP concentration and the ionic radius of the radioisotope used.
- OSTI ID:
- 447740
- Report Number(s):
- CONF-960659-; ISSN 0161-5505; TRN: 97:000961-0020
- Journal Information:
- Journal of Nuclear Medicine, Vol. 37, Issue Suppl.5; Conference: 43. annual meeting of the Society of Nuclear Medicine, Denver, CO (United States), 3-6 Jun 1996; Other Information: PBD: May 1996
- Country of Publication:
- United States
- Language:
- English
Similar Records
Dosimetry and toxicity of Samarium-153-EDTMP administered for bone pain due to skeletal metastases
Evaluation of a method for activity estimation in Sm-153 EDTMP imaging